Heidi Health hits $900m valuation with $340m raise for NHS AI push

General Catalyst and Blackbird back the NHS's sole AI documentation supplier as clinical AI regulation and workforce capacity collide.

By Disrupts Editorial Team Thu, 1 October 2026 AI level 2 of 5

AI level 2 of 5: drafted by our AI editorial assistant from the company's announcement; fact-checked, edited and signed off by Mark Walker, Editorial Director. What the levels mean

A white robotic arm precisely places a silver rectangular component onto a grid of similar components on a conveyor belt in a bright, automated factory setting.

Heidi Health, the AI clinical documentation platform embedded across large swathes of England's NHS, has closed a combined US$340 million funding package that values the company at US$900 million. The raise comprises a US$100 million Series C equity round led by Blackbird, with London-based Phoenix Court, Point72 Private Investments and Headline participating, alongside a separate US$240 million growth investment channelled through General Catalyst's Customer Value Fund. The distinction matters: the equity round sets the valuation, while the General Catalyst tranche is structured as large-scale go-to-market capacity, a model that blurs the line between venture financing and outsourced commercial infrastructure.

The funding lands at an inflection point for clinical AI in the UK. Heidi was earlier this year appointed sole supplier on the largest clinical AI documentation contract in NHS history, covering 15 acute and community trusts, every Midlands integrated care board and 1,239 GP practices. The company reports that its platform has now supported more than 175 million patient visits across 190 countries and 110 languages, up from 73 million at its Series B. Annual recurring revenue reportedly grew from US$1 million to US$50 million between launch and April 2026.

From scribe to clinical operating layer

Heidi's positioning has shifted materially since its early days as an AI transcription tool. The platform now integrates with NHS electronic health record systems, offers Heidi Evidence (a point-of-care clinical guidance tool that has fielded more than 10 million queries since March 2026), and has shipped its first hardware device, Remote, a wearable microphone designed for use across surgical and community settings. Dr Thomas Kelly, co-founder and CEO, framed the ambition plainly: "From the day I started Heidi, the ambition was always bigger than writing doctor's notes. I imagined AI sitting alongside clinicians throughout their work, from documenting consultations to helping carry out the work that follows them."

The company says it has returned more than 10 million clinical hours to UK clinicians since launch, a figure it intends to scale further as the platform moves deeper into administrative workflow automation. UK headcount has grown 123% in the past year, from 30 to 67 people, with plans to double again over the next 12 months. A meaningful portion of the new capital is earmarked for UK regulatory and clinical safety work, a signal that Heidi is actively engaging with the emerging regulatory architecture for clinical AI in the UK and Europe rather than waiting for frameworks to crystallise.

The convergence read-across: workforce, capital and regulatory arbitrage

The strategic stakes here extend well beyond a single health-tech raise. The UK Government's 10-Year Health Plan for England explicitly targets AI as every clinician's trusted assistant, creating a state-endorsed procurement environment that few other jurisdictions can match in scale or clarity of mandate. For cross-sector investors, Heidi's trajectory illustrates a broader pattern: AI infrastructure companies are finding that deeply regulated public-sector verticals, once considered too slow, now offer durable, high-retention revenue bases that justify premium valuations.

The General Catalyst Customer Value Fund structure is itself a signal worth watching. Rather than conventional growth equity, it functions as committed commercial deployment capital, embedding the investor's incentives directly into the portfolio company's go-to-market motion. If the model proves replicable, it could reshape how AI platforms in regulated industries, defence procurement software, financial compliance tooling, and clinical AI alike, access expansion capital without diluting equity at scale.

Internationally, Heidi's deployments in Australia and New Zealand (including every emergency department in New Zealand) suggest the NHS contract is functioning as a reference credential for anglophone health systems more broadly. The regulatory groundwork being funded by this round, aligned to NHS requirements, GDPR, ISO 27001 and ISO 42001, positions Heidi to move quickly as clinical AI regulation firms up across European markets. The companies best placed to capture that opportunity will be those that built compliance infrastructure before the rules were fully written.